Reviva Pharmaceuticals Files 8-K with Material Agreement Details
Ticker: RVPH · Form: 8-K · Filed: Jun 26, 2025
Sentiment: neutral
Topics: material-agreement, filing, pharmaceuticals
TL;DR
REVIVA files 8-K on June 26, 2025, reporting a material definitive agreement.
AI Summary
On June 26, 2025, Reviva Pharmaceuticals Holdings, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/exhibits. Reviva Pharmaceuticals Holdings, Inc. was formerly known as Tenzing Acquisition Corp. until June 6, 2018.
Why It Matters
This 8-K filing signals a significant development for Reviva Pharmaceuticals, likely involving a new contract or partnership that could impact its business operations and future growth.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, but the specific nature of the agreement is not detailed in this summary.
Key Players & Entities
- REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — Registrant
- Tenzing Acquisition Corp. (company) — Former company name
- June 26, 2025 (date) — Date of report
- June 6, 2018 (date) — Date of name change
FAQ
What is the nature of the material definitive agreement filed by Reviva Pharmaceuticals?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the summary information.
When was the 8-K report filed?
The 8-K report was filed on June 26, 2025.
What was Reviva Pharmaceuticals Holdings, Inc. previously named?
Reviva Pharmaceuticals Holdings, Inc. was formerly known as Tenzing Acquisition Corp.
What is the primary business of Reviva Pharmaceuticals Holdings, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code for Reviva Pharmaceuticals Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Where is Reviva Pharmaceuticals Holdings, Inc. located?
The company's business and mailing address is 10080 N Wolfe Road, Suite SW3-200, Cupertino, CA 95014.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH).